Fengjiang Liu
ShanghaiTech University
31 Papers
215 Citations
Fengjiang Liu is an academic researcher from ShanghaiTech University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 10, co-authored 17 publications. Previous affiliations of Fengjiang Liu include Chinese Academy of Sciences.
Chat about Author
Papers
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin,Zhenming Jin,Xiaoyu Du,Yechun Xu,Yong-Qiang Deng,Meiqin Liu,Yao Zhao,Bing Zhang,Xiaofeng Li,Leike Zhang,Chao Peng,Yinkai Duan,Jing Yu,Lin Wang,Kailin Yang,Fengjiang Liu,Ren-Di Jiang,Xing-Lou Yang,Tian You,Liu X,Xiuna Yang,Fang Bai,Hong Liu,Xiang Liu,Luke W. Guddat,Wenqing Xu,Wenqing Xu,Gengfu Xiao,Cheng-Feng Qin,Zhengli Shi,Hualiang Jiang,Hualiang Jiang,Zihe Rao,Zihe Rao,Zihe Rao,Haitao Yang +35 more
TL;DR: A programme of structure-assisted drug design and high-throughput screening identifies six compounds that inhibit the main protease of SARS-CoV-2, demonstrating the ability of this strategy to isolate drug leads with clinical potential.
Structure of the RNA-dependent RNA polymerase from COVID-19 virus.
Yan Gao,Yan Gao,Liming Yan,Yucen Huang,Fengjiang Liu,Yao Zhao,Lin Cao,Tao Wang,Qianqian Sun,Zhenhua Ming,Lianqi Zhang,Ji Ge,Litao Zheng,Ying Zhang,Haofeng Wang,Haofeng Wang,Yan Zhu,Chen Zhu,Tianyu Hu,Tian Hua,Bing Zhang,Xiuna Yang,Jun Li,Haitao Yang,Zhi-Jie Liu,Wenqing Xu,Luke W. Guddat,Quan Wang,Zhiyong Lou,Zihe Rao +29 more
TL;DR: The structure of the COVID-19 virus polymerase essential for viral replication provides a basis for the design of new antiviral drugs that target viral RdRp, also named nsp12, and it appears to be a primary target for the antiviral drug remdesivir.
1.5K
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.
Wenhao Dai,Wenhao Dai,Bing Zhang,Xia Ming Jiang,Haixia Su,Jian Li,Jian Li,Yao Zhao,Xiong Xie,Zhenming Jin,Jingjing Peng,Fengjiang Liu,Chunpu Li,You Li,Fang Bai,Haofeng Wang,Xi Cheng,Xiaobo Cen,Shulei Hu,Xiuna Yang,Jiang Wang,Xiang Liu,Gengfu Xiao,Hualiang Jiang,Zihe Rao,Lei Ke Zhang,Yechun Xu,Haitao Yang,Hong Liu +28 more
TL;DR: Two peptidomimetic aldehydes were designed, synthesized, and evaluated as antiviral drug candidates, and both exhibited excellent inhibitory activity and potent anti-SARS-CoV-2 infection activity.
1.4K
Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase.
Quan Wang,Jiqin Wu,Haofeng Wang,Haofeng Wang,Yan Gao,Qiaojie Liu,An Mu,An Mu,Wenxin Ji,Wenxin Ji,Liming Yan,Yan Zhu,Chen Zhu,Xiang Fang,Xiaobao Yang,Yucen Huang,H. Gao,H. Gao,Fengjiang Liu,Ji Ge,Qianqian Sun,Xiuna Yang,Wenqing Xu,Zhi-Jie Liu,Haitao Yang,Zhiyong Lou,Biao Jiang,Luke W. Guddat,Peng Gong,Zihe Rao,Zihe Rao,Zihe Rao +31 more
TL;DR: The molecular basis of SARS-CoV-2 RNA replication is examined by determining the cryo-EM structures of the stalled pre-/post- translocated polymerase complexes and the inhibition mechanisms of the triphosphate metabolite of remdesivir are investigated through structural and kinetic analyses.
782
Structure-based drug design, virtual screening and high-throughput screening rapidly identify antiviral leads targeting COVID-19
Zhenming Jin,Zhenming Jin,Xiaoyu Du,Yechun Xu,Yong-Qiang Deng,Meiqin Liu,Yao Zhao,Bing Zhang,Xiaofeng Li,Leike Zhang,Chao Peng,Yinkai Duan,Jing Yu,Lin Wang,Kailin Yang,Fengjiang Liu,Ren-Di Jiang,Xing-Lou Yang,Tian You,Liu X,Xiuna Yang,Fang Bai,Hong Liu,Xiang Liu,Luke W. Guddat,Wenqing Xu,Wenqing Xu,Gengfu Xiao,Cheng-Feng Qin,Zhengli Shi,Hualiang Jiang,Hualiang Jiang,Zihe Rao,Zihe Rao,Zihe Rao,Haitao Yang +35 more
TL;DR: The results demonstrate the efficacy of this screening strategy, and establishes a new paradigm for the rapid discovery of drug leads with clinical potential in response to new infectious diseases where no specific drugs or vaccines are available.